Nipro Sustainability Profile
Nipro Corporation, commonly referred to as Nipro, is a leading global player in the medical and pharmaceutical industries, headquartered in Japan. Established in 1954, the company has expanded its operations across key regions, including Asia, Europe, and North America, solidifying its presence in the healthcare sector. Nipro is renowned for its innovative medical devices, pharmaceutical products, and advanced manufacturing solutions. Its core offerings include dialysis products, intravenous therapy systems, and a range of pharmaceutical packaging solutions, distinguished by their quality and reliability. With a commitment to enhancing patient care, Nipro has achieved significant milestones, including numerous certifications and awards for excellence in manufacturing. The company’s strong market position is underscored by its dedication to research and development, ensuring it remains at the forefront of medical technology advancements.
DitchCarbon Score
How does Nipro's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nipro's score of 29 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nipro's reported carbon emissions
In 2024, Nipro's total carbon emissions from Scope 1 and 2 amounted to approximately 409,000,000 kg CO2e. This represents a decrease from 2023, where emissions were about 504,000,000 kg CO2e, and from 2022, which recorded around 532,000,000 kg CO2e. The trend indicates a commitment to reducing emissions over the years, although specific reduction targets or initiatives have not been disclosed. Nipro has not reported any Scope 3 emissions data, nor have they set any Science-Based Targets Initiative (SBTi) reduction targets. The company does not appear to have cascaded emissions data from a parent or related organization, as all data is sourced directly from Nipro Corporation. Overall, while Nipro has shown a positive trend in reducing its Scope 1 and 2 emissions, further transparency regarding specific climate commitments and future reduction strategies would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Nipro's Industry?
How Carbon Intensive is Nipro's Location?
Nipro's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Nipro has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
NxStage Medical, Inc.
B. Braun Melsungen AG
Kawasumi Laboratories, Incorporated
GE HealthCare
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.